These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 12594453)
1. Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). Gheorghiade M; Gattis WA; Adams KF; Jaffe AS; O'Connor CM; ; Am Heart J; 2003 Feb; 145(2 Suppl):S55-7. PubMed ID: 12594453 [No Abstract] [Full Text] [Related]
2. The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). Gheorghiade M; Gattis Stough W; Adams KF; Jaffe AS; Hasselblad V; O'Connor CM Am J Cardiol; 2005 Sep; 96(6A):18G-25G. PubMed ID: 16181819 [TBL] [Abstract][Full Text] [Related]
3. Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC. Mehra MR; McCluskey T; Barr M; Bourge RC; Jessup ML; Mancini D; Radovancevic B; Rayburn B; Taylor DO; Lilly-Hersley J; Linde P Am Heart J; 2007 Jun; 153(6):932-40. PubMed ID: 17540193 [TBL] [Abstract][Full Text] [Related]
4. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Burger AJ; Horton DP; LeJemtel T; Ghali JK; Torre G; Dennish G; Koren M; Dinerman J; Silver M; Cheng ML; Elkayam U; Am Heart J; 2002 Dec; 144(6):1102-8. PubMed ID: 12486437 [TBL] [Abstract][Full Text] [Related]
5. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure. Aronson D; Burger AJ Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294 [TBL] [Abstract][Full Text] [Related]
6. B-type natriuretic peptide: from bench to bedside. Adams KF; Mathur VS; Gheorghiade M Am Heart J; 2003 Feb; 145(2 Suppl):S34-46. PubMed ID: 12594450 [No Abstract] [Full Text] [Related]
7. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Arnold LM; Crouch MA; Carroll NV; Oinonen MJ Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484 [TBL] [Abstract][Full Text] [Related]
8. Observation unit treatment of heart failure with nesiritide: results from the proaction trial. Peacock WF; Holland R; Gyarmathy R; Dunbar L; Klapholz M; Horton DP; de Lissovoy G; Emerman CL J Emerg Med; 2005 Oct; 29(3):243-52. PubMed ID: 16183441 [TBL] [Abstract][Full Text] [Related]
9. Nesiritide for decompensated congestive heart failure. Med Lett Drugs Ther; 2001 Nov; 43(1118):100-1. PubMed ID: 11707752 [No Abstract] [Full Text] [Related]
10. Nesiritide Therapy Is Associated With Better Clinical Outcomes Than Dobutamine Therapy in Heart Failure. Kong LG; Wang CL; Zhao D; Wang B Am J Ther; 2017; 24(2):e181-e188. PubMed ID: 26164026 [TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure. Gerhard T; Zineh I; Winterstein AG; Hartzema AG Pharmacotherapy; 2006 Jan; 26(1):34-43. PubMed ID: 16509026 [TBL] [Abstract][Full Text] [Related]
12. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144 [TBL] [Abstract][Full Text] [Related]
13. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. Yancy CW; Krum H; Massie BM; Silver MA; Stevenson LW; Cheng M; Kim SS; Evans R; Am Heart J; 2007 Apr; 153(4):478-84. PubMed ID: 17383282 [TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the enoximone clinical trials program. Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960 [TBL] [Abstract][Full Text] [Related]
15. Critical review and recommendations for nesiritide use in the emergency department. Collins SP; Hinckley WR; Storrow AB J Emerg Med; 2005 Oct; 29(3):317-29. PubMed ID: 16183453 [TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of serial home infusions of nesiritide for advanced heart failure. Chung ES; Menon SG; Daly KA; Atkinson J; Peterson T; Robertson R; Ibanez K; Kereiakes DJ Am J Cardiol; 2006 May; 97(9):1370-3. PubMed ID: 16635613 [TBL] [Abstract][Full Text] [Related]
17. Acutely decompensated heart failure in a county emergency department: a double-blind randomized controlled comparison of nesiritide versus placebo treatment. Miller AH; Nazeer S; Pepe P; Estes B; Gorman A; Yancy CW Ann Emerg Med; 2008 May; 51(5):571-8. PubMed ID: 18304693 [TBL] [Abstract][Full Text] [Related]
18. Digoxin in heart failure. Chadwell M; French L J Fam Pract; 1997 May; 44(5):442. PubMed ID: 9152256 [No Abstract] [Full Text] [Related]
19. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. de Lissovoy G; Stier DM; Ciesla G; Munger M; Burger AJ Am J Cardiol; 2003 Sep; 92(5):631-3. PubMed ID: 12943895 [TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Hernandez AF; O'Connor CM; Starling RC; Reist CJ; Armstrong PW; Dickstein K; Lorenz TJ; Gibler WB; Hasselblad V; Komajda M; Massie B; McMurray JJ; Nieminen M; Rouleau JL; Swedberg K; Califf RM Am Heart J; 2009 Feb; 157(2):271-7. PubMed ID: 19185633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]